The FDA has granted approval to Ascend Laboratories for its ANDA (ANDA208315) marketing application for Mycophenolic Acid, a generic tablets offering for mycophenolate sodium. This clearance is expected to introduce a cost-effective alternative to the brand, potentially challenging market share and intensifying competitive pricing dynamics within the immunosuppressive therapy sector.